Search results

1308 results

Sorted by Relevance . Sort by Date

  1. Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA341)

    Evidence-based recommendations on apixaban (Eliquis) for treating and preventing deep vein thrombosis (DVT) or pulmonary embolism

  2. Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)

    Evidence-based recommendations on vedolizumab (Entyvio) for treating moderately to severely active ulcerative colitis in adults

  3. Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) with chlorambucil for treating untreated chronic lymphocytic leukaemia

  4. Omalizumab for previously treated chronic spontaneous urticaria (TA339)

    Evidence-based recommendations on omalizumab (Xolair) for treating previously treated severe chronic spontaneous urticaria (hives)

  5. Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)

    Evidence-based recommendations on rivaroxaban (Xarelto) for preventing adverse outcomes after acute management of acute coronary syndrome (ACS)

  6. Empagliflozin in combination therapy for treating type 2 diabetes (TA336)

    Evidence-based recommendations on empagliflozin (Jardiance) in combination therapy for treating type 2 diabetes

  7. Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)

    Evidence-based recommendations on rifaximin (Targaxan) for preventing episodes of overt hepatic encephalopathy

  8. Holoclar for treating limbal stem cell deficiency after eye burns (TA467)

    Evidence-based recommendations on Holoclar for treating limbal stem cell deficiency in adults after eye burns

  9. Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes (TA47)

    Evidence-based recommendations on glycoprotein IIb/IIIa inhibitors(abciximab [ReoPro], eptifibatide [Integrilin], tirofiban [Aggrastat]) for acute coronary

  10. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C (TA75)

    Evidence-based recommendations on interferon alfa (pegylated and non-pegylated) and ribavirin for treating chronic hepatitis C

  11. Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia (TA77)

    Evidence-based recommendations using zolpidem and zopiclone (the Z-drugs) for the short-term management of insomnia (sleeplessness) in adults

  12. Fluid-filled thermal balloon and microwave endometrial ablation techniques for heavy menstrual bleeding (TA78)

    Evidence-based recommendations on fluid-filled thermal balloon and microwave endometrial ablation techniques for treating heavy menstrual bleeding (HMB)

  13. Frequency of application of topical corticosteroids for atopic eczema (TA81)

    Evidence-based recommendations on the frequency of application of topical corticosteroids for treating atopic eczema (atopic dermatitis)

  14. Denosumab for the prevention of osteoporotic fractures in postmenopausal women (TA204)

    Evidence-based recommendations on denosumab (Prolia) for preventing osteoporotic fragility fractures in postmenopausal women

  15. Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)

    Evidence-based recommendations on trastuzumab (Herceptin) for treating adenocarcinoma (HER2-positive metastatic gastric cancer/stomach cancer)

  16. Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (TA209)

    Evidence-based recommendations on imatinib (Glivec) for treating unresectable (inoperable) and/or metastatic gastrointestinal stromal tumours (GISTs)

  17. Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)

    Evidence-based recommendations on human growth hormone (somatropin) for treating growth failure in children

  18. Infliximab and adalimumab for the treatment of Crohn's disease (TA187)

    Evidence-based recommendations on infliximab (Remicade) and adalimumab (Humira) for treating Crohn's disease in adults

  19. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)

    Evidence-based recommendations on etanercept (Enbrel) infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis

  20. Dronedarone for the treatment of non-permanent atrial fibrillation (TA197)

    Evidence-based recommendations on dronedarone (Multaq) for treating non-permanent atrial fibrillation (AF)

  21. Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (TA193)

    Evidence-based recommendations on rituximab (MabThera) for treating relapsed or refractory chronic lymphocytic leukaemia (CLL)

  22. Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)

    Evidence-based recommendations on topotecan (Hycamtin) for treating recurrent stage IVB (stage 4B) cervical cancer (cancer of the cervix)

  23. Trabectedin for the treatment of advanced soft tissue sarcoma (TA185)

    Evidence-based recommendations on trabectedin (Yondelis) for treating advanced soft tissue sarcoma (tumours/cancer)

  24. Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (TA221)

    Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune (idiopathic) thrombocytopenic purpura (ITP)

  25. Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (TA223)

    Evidence-based recommendations on cilostazol (Pletal), naftidrofuryl oxalate (Praxilene), pentoxifylline (Trental 400) and inositol nicotinate (Hexopal)

  26. Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs (TA225)

    Evidence-based recommendations on golimumab (Simponi) for treating rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs

  27. Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion (TA229)

    Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating macular oedema secondary to retinal vein occlusion

  28. Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) (TA23)

    Evidence-based recommendations on temozolomide (Temodal) for malignant glioma in children over 3 years, young people and adults.

  29. Bivalirudin for the treatment of ST-segment-elevation myocardial infarction (TA230)

    Evidence-based recommendations on bivalirudin (Angiox) for treating ST-segment-elevation myocardial infarction (STEMI)

  30. Guidance on the use of electroconvulsive therapy (TA59)

    Evidence-based recommendations on electroconvulsive therapy (ECT) for treating severe depressive illness, mania and catatonia

  31. Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer (TA100)

    Evidence-based recommendations on capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer in adults

  32. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma (TA137)

    Evidence-based recommendations on rituximab for treating relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma in adults

  33. Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies (TA171)

    Evidence-based recommendations on lenalidomide (Revlimid) for treating multiple myeloma in adults who have had at least 2 prior therapies

  34. Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (TA145)

    Evidence-based recommendations on cetuximab (Erbitux) for treating locally advanced squamous cell cancer of the head and neck in adults